NEW YORK , May 3, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of two individuals whose employment commenced in April 2024... Read More

NEW YORK , April 4, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company's Compensation Committee, as a material inducement to the employment of one individual whose employment commenced in March... Read More

Increases 2024 Treatment Site Activation Guidance to 20 Sites QUEENSBURY, N.Y. , March 26, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported recent business highlights and financial results for the fourth quarter and full year ended December 31, 2023 . Recent... Read More

NEW YORK , March 20, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, confirmed the closing of the previously announced private placement with certain accredited investors comprised of existing investors, Delcath Executives and members of its Board of Directors, for a private placement transaction (the... Read More

NEW YORK , March 19, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on March 26, 2024 , at 8:30 AM Eastern Time to discuss results for its fourth quarter and year ended December 31, 2023 and provide a business update. Conference Call Information To participate... Read More

NEW YORK , March 18, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Martha S. Rook as its new Chief Operating Officer (COO). Martha S. Rook , Ph.D., is an experienced industry leader who brings more than 25 years of academic and industry... Read More

NEW YORK , March 15, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that it has entered into a securities purchase agreement with certain accredited investors comprised of existing investors, Delcath Executives and members of its Board of Directors, for a private placement transaction (the... Read More

NEW YORK , March 8, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of three individuals whose employment commenced in... Read More

NEW YORK , March 8, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that Company management will be attending the following upcoming investor conferences: Leerink Partners Global Biopharma Conference Date: March 13, 2024 Location: Miami Beach, FL 36 th Annual ROTH Conference Date: March 18 -... Read More

NEW YORK , Feb. 22, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Company has launched a Healthcare Setting Locator (Locator) on the hepzatokit.com website. Potential patients, caregivers, and healthcare providers may use the Locator to identify healthcare settings, offering... Read More

NEW YORK , Feb. 16, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of three individuals whose employment commenced in January... Read More

NEW YORK , Jan. 31, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Centers for Medicare & Medicaid Services ("CMS") has established a permanent and product-specific J-code (J9248) for HEPZATO. The J-code will become effective on April 1, 2024 . J-codes are a form of Healthcare... Read More

NEW YORK , Jan. 23, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that Gerard Michel , CEO, will participate in a fireside chat moderated by Bill Maughan Ph.D., Senior Analyst at Canaccord Genuity, at the Lytham Partners 2024 Investor Select Conference. Management will also host virtual... Read More

NEW YORK , Jan. 16, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the first commercial use of HEPZATO KIT for the treatment of metastatic uveal melanoma (mUM). The procedure took place at Moffitt Cancer Center in Tampa, Florida by Dr. Jonathan S. Zager , M.D., Chief Academic Officer; Senior... Read More

NEW YORK , Jan. 12, 2024 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of two individuals whose employment commenced in December... Read More

Retrospective Analysis of Changes in Patients with Metastatic Uveal Melanoma treated with Chemosat Hepatic Delivery System Results Support that Utilizing Delcath's HDS to Administer High-Dose Melphalan to the Liver Is Well Tolerated by Patients NEW YORK , Dec. 7, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the... Read More

NEW YORK , Nov. 15, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee, as a material inducement to the employment of five individuals. The grant totaled the right to... Read More

NEW YORK , Nov. 13, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the third quarter ended September 30, 2023 . Recent Business Highlights Received approval from the US Food and Drug Administration (FDA) for HEPZATO... Read More

NEW YORK , Nov. 6, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on November 13, 2023 , at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30 , 2023. Conference Call Information To participate in this event, dial approximately 5... Read More

Retrospective Comparison of Two Liver Directed Therapies in Patients with Metastatic Uveal Melanoma Significantly Longer Overall Survival for Patients Treated with Chemosat vs. SIRT (17 and 9.9 months, respectively; p=0.006) NEW YORK , Oct. 16, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional... Read More

NEW YORK , Oct. 10, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it will be participating in the Lytham Partners Fall 2023 Investor Conference taking place virtually on Tuesday, October 17, 2023 . Company Webcast Gerard Michel , CEO, will be participating in a fireside chat. The Company's... Read More

NEW YORK , Oct. 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the Roth MKM Healthcare Opportunities Conference in New York . Delcath CEO, Gerard Michel will present on October 12 at 11:45 AM ET . A webcast of the presentation will be available at ROTH - 2023 Healthcare Opportunities... Read More

NEW YORK , Sept. 27, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, in the form of a total of 86,000 shares of the Company's common stock, outside of the Company's Omnibus 2020 Equity Incentive Plan as amended ("Plan"),... Read More

Independent Investigator Study Compared Two Liver Directed Therapies in Patients with Metastatic Uveal Melanoma Significantly Longer Overall Survival for Patients Treated with Chemosat vs. SIRT (516 and 301 days, respectively; p=0.006) NEW YORK , Sept. 11, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver,... Read More

NEW YORK , Sept. 5, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the H.C Wainwright 25 th Annual Global Investor Conference. Delcath CEO, Gerard Michel will present on September 13 at 11:00 AM ET . A webcast of the presentation will be available at... Read More

NEW YORK , Sept. 1, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today that it raised approximately $35 million through the exercise of all the Tranche A warrants issued as part the previously announced March 29, 2023 Private Investment in Public Equity (PIPE) financing. The warrants were... Read More

A Retrospective Comparative Study of SIRT and CS-PHP for Liver Targeted Therapy of Patients with Metastatic Uveal Melanoma NEW YORK , Aug. 29, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced an oral presentation by independent investigators at the Cardiovascular and Interventional... Read More

HEPZATO KIT is the only FDA approved liver-directed therapy to treat metastatic uveal melanoma Approval includes treatment naïve and previously treated patients and is not limited by HLA genotype Delcath to hold Business Update Call on August 15, 2023 at 8:00 a.m. Eastern Time NEW YORK , Aug. 14, 2023 /PRNewswire/ -- Delcath... Read More

NEW YORK , Aug. 9, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) ("Delcath" or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the second quarter ended June 30, 2023 . Recent Business Highlights During and since the second quarter, Delcath: Has continued to communicate with the... Read More

NEW YORK , Aug. 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that it plans to report the Company's 2Q23 earnings and issue its Form 10-Q the week of August 7, 2023 . Subsequently, shortly after the FDA's decision on its HEPZATO™ KIT's new drug application ("NDA") resubmission, Delcath expects... Read More

NEW YORK , June 21, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted equity awards, previously approved by the Company's Compensation Committee and the Board of Directors, as a material inducement to employment for two individuals, the Chief... Read More

NEW YORK , June 20, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Vojislav "Vojo" Vukovic as its new Chief Medical Officer (CMO). Dr. Vukovic is an experienced drug development executive with a distinguished career in cancer... Read More

NEW YORK , June 7, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that the Company has appointed Sandra Pennell as its new Senior Vice President of Finance. Ms. Pennell will also serve as an Executive Officer of the Company and its Principal Accounting... Read More

NEW YORK , May 12, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH) (Delcath or the "Company"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and certain preliminary financial results for the first quarter ended March 31, 2023 . Recent Business Highlights During and since the first quarter, Delcath: Received an... Read More

NEW YORK , May 9, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will be participating in the Lytham Partners Spring 2023 Investor Conference taking place virtually on Thursday, May 18, 2023 . Industry Panel Delcath CEO Gerard Michel will be participating on a panel titled Advancements in the Fight Against... Read More

NEW YORK , May 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced today it will host a conference call on May 12, 2023 , at 8:30 AM Eastern Time to discuss results for its first quarter ended March 31, 2023 . Conference Call Information To participate in this event, dial approximately 5 to 10... Read More

Amendment with Avenue Venture Opportunities Fund, L.P. provides for an interest-only period from March 31, 2023 to September 30, 2023 and defers $4.3 million in principal payments NEW YORK , April 3, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced it reached an agreement to amend its existing... Read More

Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by existing investor, Rosalind Advisors $25 million financing upfront with up to an additional $60 million tied to satisfaction of milestones Aggregate financing expected to be sufficient to fund Company through potential approval of HEPZATO and commercialization NEW YORK , March... Read More

NEW YORK , March 27, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2022 . Recent Business Highlights During and since the fourth quarter, Delcath Systems, Inc. (Delcath or the Company): Received... Read More

Led by Vivo Capital with participation from Logos Capital, BVF Partners LP, Stonepine Capital Management, LLC, Serrado Capital LLC and supported by existing investor, Rosalind Advisors $25 million financing upfront with up to an additional $60 million tied to satisfaction of milestones Aggregate financing expected to be sufficient to fund Company through potential approval of HEPZATO and commercialization NEW YORK , March... Read More

NEW YORK , March 27, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH ), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that the US Food and Drug Administration (FDA) has accepted Delcath Systems, Inc.'s (Delcath) new drug application resubmission for HEPZATO™ Kit (melphalan hydrochloride for Injection/Hepatic Delivery System) seeking approval for... Read More

NEW YORK , Feb. 16, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced that its Board of Directors has voted to appoint John R. Sylvester as Delcath's new Chairman. Mr. Sylvester has served as a Director of Delcath since July 2019 and has extensive experience building interventional oncology... Read More

NEW YORK , Feb. 14, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announced it submitted a new drug application (NDA) resubmission to the US Food and Drug Administration (FDA) for the HEPZATO™ Kit (melphalan hydrochloride for Injection/Hepatic Delivery System or Melphalan/HDS) seeking approval for the... Read More

NEW YORK , Jan. 30, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will participate at the BTIG MedTech, Digital Health, Life Sciences, & Diagnostics Tools Conference in Snowbird, Utah on February 14 to 16 . Delcath CEO, Gerard Michel will be conducting one-on-one meetings. To request a one-on-one meeting... Read More

Updated results in seven patients with advanced uveal melanoma treated with CHEMOSAT and ipilimumab plus nivolumab show a Median PFS of 29.1 months All seven patients treated still alive as of last follow-up at a median follow-up of 29.1 months NEW YORK , Jan. 17, 2023 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an... Read More

NEW YORK , Dec. 16, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that the Company granted an equity award, previously approved by the Company's Compensation Committee, as a material inducement to employment for one individual. The employee received a total of 12,500 shares of the Company's... Read More

NEW YORK , Dec. 13, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the closing of the previously announced private placement with certain accredited investors (the "Private Placement"). Delcath issued and sold 1,448,889 shares of its common stock (the "Common Stock") at a price per share of... Read More

NEW YORK , Dec. 8, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that it has entered into a securities purchase agreement with certain accredited investors for a private placement transaction... Read More

Results show that percutaneous hepatic perfusion with CHEMOSAT ® is an effective and safe treatment option for patients with advanced cholangiocarcinoma and has the potential to prolong life in patients with inoperable, treatment-refractory liver metastases. NEW YORK , Dec. 5, 2022 /PRNewswire/ -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic... Read More